Corporate earnings could reignite AI stock rally this week
This week, the AI craze on the world's stock markets risks flaring up again. Reports from American heavyweights such as Alphabet, Intel and IBM will be important indicators.
TechnologyThis week, the AI craze on the world's stock markets risks flaring up again. Reports from American heavyweights such as Alphabet, Intel and IBM will be important indicators.
TechnologyThe leading indices on the New York Stock Exchange were mostly higher on Tuesday, with better-than-expected inflation figures helping to lift sentiment.
BusinessIBM shares plunge in futures trading, down more than 20 percent, after a profit warning.
BusinessTechnology company IBM beat analysts' expectations in its quarterly report on Wednesday evening, but its stock fell in after-hours trading.
BusinessA valuation of three trillion kronor, recurring stock-market chaos and close collaboration with the Pentagon - in five years, Anthropic has risen to the top of the AI pyramid. Can it stay there without abandoning its own fundamentals?
TechnologyLouis Gerstner, the business executive often seen as the savior of IBM, has died.
BusinessAll three leading stock market indexes in the US fell on the first day of the trading week.
BusinessTechnology company IBM is buying data streaming platform Confluent for $11 billion (equivalent to SEK 104 billion) including debt. The acquisition is IBM's largest since its $34 billion purchase of software company Red Hat in 2019.
BusinessEnergy companies and technology giants were among the winners on the stock exchange in the USA since President Donald Trump announced harsh sanctions against the Russian oil industry.
BusinessAfter four brutal weeks, the New York stock exchange went into the red with rising prices for the second trading day in a row.
BusinessThe IT giant Intel is facing a painful billion-loss – and is forced to lay off thousands of employees. The main reason for the setback is that the company failed to compete in the AI race. They got a taste of their own medicine, says Magnus Mähring, professor at the Stockholm School of Economics.
Business